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Abstract
Chromosome aberrations have long been studied in an effort to identify susceptibility genes for
schizophrenia. Chromosome 22q11.2 microdeletion is associated with DiGeorge and
Velocardiofacial syndromes (DG/VCF) and provides the most convincing evidence of an association
between molecular cytogenetic abnormality and schizophrenia. In addition, this region is one of the
best replicated linkage findings for schizophrenia. Recently, the reciprocal microduplication on
22q11.2 has been reported as a new syndrome. Preliminary data indicates that individuals with
these duplications also suffer from neuropsychiatric disorders. In this study we have investigated
the appropriateness of testing schizophrenia patients for the 22q11.2 microduplication. We used
multiplex ligation-dependent probe amplification (MLPA) to measure copy number changes on the
22q11.2 region in a sample of 190 patients with schizophrenia. Our results corroborate the
prevalence of the 22q11.2 microdeletion in patients with schizophrenia and clinical features of DG/
VCFS and do not suggest an association between 22q11.2 microduplication and schizophrenia.
Findings
Low copy repeats (LCRs) on chromosome 22q11.2 medi-
ate chromosomal rearrangements leading to recurrent
deletions, duplications and translocations [1]. The
22q11.2 microdeletion is responsible for the DiGeorge
and Velocardiofacial Syndromes (DG/VCFS) (OMIM
#188400 and #192430). These syndromes are associated
with variable phenotypic features that includes cardiac
defects, palate anomalies, characteristic physiognomy,
learning difficulties and relatively high frequency of severe
mental illness like schizophrenia. The majority of human
chromosome 22q11.2 microdeletions (87%) are ~3 Mb
in size, whereas a small proportion (8%) involve smaller
nested 1.5 Mb microdeletion [2]. The reciprocal microdu-
plication has been reported in several individuals [3]. This
new chromosomal syndrome was identified in patients
ascertained on the basis of to DG/VCFS-like features and
up to 48 cases of the 22q11.2 microduplication have been
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reported [4]. The clinical presentation of 22q11.2 micro-
duplication cases is highly variable, ranging from severe
congenital malformations that lead to early death, to iso-
lated mild learning disabilities. Most of the reported indi-
viduals are infants or children at present, in who the
existence of neuropsychiatry disorders has not yet been
fully assessed. However, preliminary data show that indi-
viduals with duplications also suffer from neuropsychiat-
ric disorders. Furthermore, characteristic traits of
impulsivity, aggression, oppositional defiant disorder,
social immaturity, short attention spans, attention deficit
disorder, and cognitive deficits have been reported in
cases of 22q11.2 microduplication [3,5-8].
Chromosome 22q11.2 region provides the most convinc-
ing evidence of an association between molecular cytoge-
netic abnormality and schizophrenia.
Although 22q11.2 microdeletion occurs in the popula-
tion at a rate of 0.016%, it has been found in up to 2% of
adult schizophrenic patients and in up to 6% of cases of
early onset schizophrenia [9,10]. Several reports suggest
that dosage changes in 22q11.2 genes could disrupt proc-
esses required for proper brain development and/or func-
tion, and contribute to increase schizophrenia
susceptibility [11,12]. Several studies have suggested link-
age between 22q11 and schizophrenia [13-15] and it is
one of the best replicated linkage findings among schizo-
phrenia patients. Meta-analysis of genome scans for bipo-
lar disorder and schizophrenia have also identified
chromosome 22q11-13 as one of the strongest linkage
regions for both syndromes [16].
These linkage findings indicate that mutations of genes on
22q11 are likely to contribute to susceptibility to schizo-
phrenia. In the same direction association studies have
reported several genes of this region associated with risk to
develop schizophrenia and bipolar disorder, including
PRODH,  COMT,  ZNF74,  PCQAP,  UFD1L,  ZDHHC8,
DGCR2 and SNAP29 [17,18]. In addition, neuroimaging
studies revealed that 22q11.2 deletion patients exhibit a
pattern of cortical gray matter reduction similar to schizo-
phrenic subjects [19]. Finally, mouse models provide evi-
dences that this region is associated with schizophrenia. A
murine model overexpressing the mouse orthologs of sev-
eral genes in this region (CDCrel,  GP1Bβ,  TBX1  and
WDR14) exhibits behavioral abnormalities consistent
with schizophrenia traits [20].
It seems extremely likely that the 22q11.2 region harbours
genes that alone, or in combination, could be causally
implicated in schizophrenia. Nowadays the phenotype of
individuals with 22q11.2 microduplication shows a wide
range of severity but some consistent findings have been
dysmorphic features, cognitive deficits and psychiatric
disorders reported in 33% of cases [6]. In this study we
decided to investigate the appropriateness of testing schiz-
ophrenia patients for 22q11.2 microduplication. We used
multiplex ligation-dependent probe amplification
(MLPA) to measure copy number changes on 22q11.2
region in a set of patients with schizophrenia.
A total of 190 Caucasian, unrelated patients with schizo-
phrenia (153 men and 40 women; age 33,3 ± 8,6 years)
were included in the study. Educational levels were
divided into the following categories: 54% of patients
have primary school (1–11 years), 26% secondary school
(12–16 years), 7% high school (17–18 years), 7% univer-
sity level and finally 6% can only read and write. Patients
were diagnosed according to DSM-IV criteria as follow:
126 paranoid, 14 disorganized, 13 undifferentiated, 9
residual, 13 schizoaffective disorder, 13 schizophreni
form disorder and 2 cases were not specificated. All cases
have been recruited at the department of mental health of
two hospitals, from Sabadell and Terrassa, after written
informed consent approved by the ethics board of the
Fundació Parc Taulí Health Corporation.
A set of MLPA probes to screen copy number changes in
the 22q11.2 region was developed according to the proce-
dures described elsewhere [21]. The set consists of 30 dif-
ferent oligonucleotides that correspond to 15 different
probes, 4 of which interrogate the 3 Mb region that is typ-
ically deleted in cases of DG/VCFS and the remaining 11
probes match to other regions of chromosome 22 and to
other autosomal region on chromosome 10 (Table 1).
One hundred and sixty patients were analyzed with this
mix of probes. Another group of 30 individuals were also
analyzed using the commercial SALSA P023 MLPA-
DiGeorge syndrome test kit (MRC-Holland, Nether-
lands). This commercial kit consists of 39 cloned probes
that interrogate different chromosomal regions associated
to DG/VCFS and Cat Eye Syndrome. In this case, the
microdeletion region is covered by seven specific probes
and a subtelomeric 22q13 control probe. All our MLPA
experiments contained the corresponding positive con-
trols (DNA from individuals previously diagnosed as car-
riers of 22q11.2 duplications or deletions) to ensure the
reliable detection of copy number gains and loses (Figure
1).
The MLPA reactions were performed essentially as
described by Schouten et al. [22]. For the data analysis we
calculated the relative probe signals using the peak heights
of PCR products. Briefly, the tracing data was normalized
by dividing each probe's peak height by the average height
of all peaks of the sample and then dividing this value by
the average normalized peak's height of the correspond-
ing locus of all the samples. The product of this calcula-Behavioral and Brain Functions 2008, 4:10 http://www.behavioralandbrainfunctions.com/content/4/1/10
Page 3 of 5
(page number not for citation purposes)
tion is termed dosage quotient (DQ). A calculated DQ
value below 0.65 was considered as indicative of a dele-
tion, and values above 1.3 are indicative of duplications.
Among the 190 schizophrenic patients analyzed, we iden-
tify two cases (EZ-117 and EZ-238) with the 22q11.2
microdeletion. This incidence of about 1% is in agree-
ment with previous estimates in the literature [23,24]. We
did not detect the reciprocal 22q11.2 microduplication.
The deleted samples were analyzed with both the in-
house and commercial MLPA assays, with similar DQ val-
ues below the 0.65 threshold. A confirmatory FISH analy-
sis was also performed (data not shown). Both patients
showed common manifestations associated with DG/
VCFS, including malformations of the cardiovascular sys-
tem (aberrant origin of subclavian artery/pulmonary sten-
osis), facial dysmorphic features (long face, small ears,
narrow palpebral fissures, prominent tubular nose), velo-
pharingeal insufficiency with severe hipernasality, motor
delay, cognitive deficit and mild mental retardation.
These two patients with the 22q11.2 microdeletion were
girls that were noted to have history of learning and
behavioural problems in the school. Both cases are diag-
nosed as hebephrenic schizophrenia with early age of
onset (12–13 years).
Subsequent family analyses in the parents showed the
22q11.2 microdeletion in the mother of one patient. The
mother with same facial appearance than her daughter
showed paranoid schizophrenia and mild mental retarda-
tion. This family has another offspring, a boy who was
diagnosed with attention-deficit hyperactivity disorder
(ADHD) during childhood. He proved to be normal by
FISH analyses (not shown).
Our study indicates that MLPA is a suitable, easy, rapid
and cost-effective method to seek for copy number varia-
tions (microdeletions and microduplications) in patients
suffering from psychiatric disorders. Furthermore, our
results confirm the prevalence of the 22q11.2 microdele-
tion in patients with schizophrenia and other clinical fea-
tures of DG/VCFS, but do not indicate any association
with the 22q11.2 microduplication. We conclude that
screening for 22q11 microduplication in patients with
schizophrenia is not indicated.
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Table 1: Probes, genes and MLPA outcome in the analysis of the 22q11.2 duplication syndrome rearrangement among patients with 
schizophrenia
Probe Location Gene Chrom Start End Length (nt) MLPA result
HIRA 22q11.21 HIRA 22 17698971 17699021 93 Del (EZ-117 and EZ-238)
TBX-1 22q11.21 TBX1 22 18150824 18150883 104 Del (EZ-117 and EZ-238)
COMT 22q11.21 COMT 22 18335516 18335575 110 Del (EZ-117 and EZ-238)
ZDHHC8 22q11.21 ZDHHC8 22 18513602 18513661 113 Del (EZ-117 and EZ-238)
RP11-307O16 22q11.22 22 20838313 20838371 101 Dup (EZ-18)
RP11-722K16 22q11.22 IGLC1 22 20999611 20999670 132 Dup (EZ-149)
RP11-757F24 22q11.22 IGLC1 22 21157367 21157421 97
RP11-281O23 22q11.22 IGLC1 22 21292358 21292410 95
RP11-50L23 22q11.22 IGLC1 22 21439794 21439859 124 Dup (EZ-6)
RP11-264C20 22q11.22 IGLC1 22 21526749 21526796 90 Dup (EZ-6), Del (EZ-105)
RP11-165G05 22q11.22 22 21655494 21655558 107 Dup (EZ-6)
CARD10 22q13.1 CARD10 10 36236312 36236371 128
CXCL12 10q11.23 CXCL12 10 44192388 44192461 116 Del (EZ-96 and EZ-125)
C10orf10 10q11.23 RASSF4 C10orf10 10 44792765 44792844 122
ZWINT 10q21 ZWINT 10 57789521 57789580 120
Del, deletion; Dup, duplication; EZ, schizophrenia sample.Behavioral and Brain Functions 2008, 4:10 http://www.behavioralandbrainfunctions.com/content/4/1/10
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